Language During Inhalational Induction
Launched by BOSTON CHILDREN'S HOSPITAL · Mar 15, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the way doctors talk to children during the start of anesthesia can affect their feelings and behavior. Specifically, it compares the use of standard language that doctors usually use with more positive, encouraging language. The goal is to see if using positive language can help reduce anxiety and negative behaviors, like confusion or distress, in children aged 5 to 10 who need anesthesia for non-emergency procedures.
To participate in this study, children must be generally healthy (classified as ASA 1 or 2) and not have any previous experiences with inhalational induction, which is a common method of starting anesthesia using gas. Children with certain conditions, like hearing difficulties or behavioral issues, are not eligible. If chosen to participate, children will be randomly assigned to either the standard language group or the positive language group, and their reactions will be observed during the process. This research could help improve the experience of children undergoing anesthesia in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA 1 and 2 (Healthy Patients)
- • Non-emergent cases
- • 5-10 year olds
- • Patients receiving inhalational induction
- Exclusion Criteria:
- • Non-English speaking
- • History of prior inhalational inductions
- • Hearing difficulty
- • Behavioral difficulty (Autism, Oppositional Defiant Disorder)
- • Patients receiving premedication other than midazolam
About Boston Children's Hospital
Boston Children's Hospital is a leading pediatric healthcare institution renowned for its commitment to advancing child health through innovative research and exceptional clinical care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in pediatric medicine to conduct rigorous and ethically sound research studies aimed at improving treatment options and outcomes for children. With a collaborative approach that integrates cutting-edge technology and multidisciplinary teams, Boston Children's Hospital is dedicated to translating scientific discoveries into practical applications that enhance the well-being of young patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
John Fiadjoe, MD
Principal Investigator
Boston Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported